How much is the latest price of cobimetinib?

Cobimetinib (Cobimetinib) is an oral MEK inhibitor, mainly used to treat BRAF V600 mutation-positive advanced melanoma and other tumors for other indications. It specifically inhibits MEK1/2 kinase activity and blocks the RAS-RAF-MEK-ERK signaling pathway, thereby inhibiting tumor cell proliferation and promoting apoptosis. It is one of the important drugs in targeted therapy.

At present, the original drug of cobimetinib has not yet been launched in China, so domestic patients cannot purchase it directly through hospital pharmacies or formal channels. Since there is no domestic listing and medical insurance information, patients who want to use this drug can only pay attention to international clinical trials or overseas drug purchase channels, and formulate treatment plans under the guidance of professional doctors.

In overseas markets, the price of cobimetinib varies greatly depending on regions and specifications. The specifications of the Turkish version of the original drug are 20mg*63 tablets, and each box sells for about more than 10,000 yuan; the European version of the original drug of the same specifications sells for about more than 40,000 yuan per box, which may be adjusted due to exchange rate fluctuations. This price reflects the research and development costs and market pricing characteristics of the original drug, which is higher for patients undergoing long-term treatment.

In addition, generic drugs of cobimetinib have been launched in overseas markets, and their drug ingredients are basically the same as the original drug. For example, generic drugs of the same specifications produced by Lao pharmaceutical factories cost about more than 3,000 yuan per box, which is highly cost-effective and provides a choice for patients with limited budgets or long-term treatment needs. However, regardless of whether it is original research or generic drugs, patients should purchase and use them through formal channels and conduct individualized dosage adjustments and efficacy monitoring in conjunction with doctor's guidance to ensure safety and efficacy.

Reference materials:https://www.drugs.com/